Arecor Therapeutics (AREC) Stock Overview
A clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AREC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Arecor Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.78 |
| 52 Week High | UK£1.00 |
| 52 Week Low | UK£0.55 |
| Beta | -0.19 |
| 1 Month Change | 32.48% |
| 3 Month Change | 19.23% |
| 1 Year Change | 6.90% |
| 3 Year Change | -58.67% |
| 5 Year Change | -68.50% |
| Change since IPO | -67.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| AREC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.7% | -0.08% | -0.7% |
| 1Y | 6.9% | -23.3% | 16.1% |
Return vs Industry: AREC exceeded the UK Biotechs industry which returned -22% over the past year.
Return vs Market: AREC underperformed the UK Market which returned 17.3% over the past year.
Price Volatility
| AREC volatility | |
|---|---|
| AREC Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AREC has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: AREC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 33 | Sarah Howell | arecor.com |
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist.
Arecor Therapeutics plc Fundamentals Summary
| AREC fundamental statistics | |
|---|---|
| Market cap | UK£29.26m |
| Earnings (TTM) | UK£932.00k |
| Revenue (TTM) | UK£1.71m |
Is AREC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AREC income statement (TTM) | |
|---|---|
| Revenue | UK£1.71m |
| Cost of Revenue | UK£448.00k |
| Gross Profit | UK£1.27m |
| Other Expenses | UK£334.00k |
| Earnings | UK£932.00k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.025 |
| Gross Margin | 73.86% |
| Net Profit Margin | 54.38% |
| Debt/Equity Ratio | 0% |
How did AREC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 00:53 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arecor Therapeutics plc is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Panmure Liberum |